Health Blog : Glaxo's Earnings Steady, Despite Avandia's Fall

Health Blog : Glaxo's Earnings Steady, Despite Avandia's Fall: "Sales of GlaxoSmithKline’s suddenly controversial diabetes drug Avandia fell 22% during the second quarter, but the decline was offset by gains for other drugs, the company said today. Net income for the quarter rose 1.4% compared with same period last year, to $2.75 billion."